# Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
Canonical URL: https://biopharmsignal.com/news/IMMX/immix-biopharma-presents-positive-nxc-201-clinical-data-at-66th-american-society-of-hematology-ash-annual-meeting-in-16-relapsed-refractory-al-amyloidosis-patients
Ticker: IMMX
Company: Immix Biopharma
Source: Immix Biopharma
Published: 2024-11-25 09:32 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p> </p> <ul><li>75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy <br /></li><li>Data will be presented on Mond

## Article Body
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy

Data will be presented on Monday, December 9, 2024 at 4:00 PM PT

LOS ANGELES, Nov.  25, 2024  (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a...
## Recent Company News
- 2026-05-22 17:15 EST — [Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 06:30 EST — [Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 06:00 EST — [Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relapsed-refractory-al-amyloidosis-clinical-trial-nexicart-2) — Source: Immix Biopharma
- 2026-04-09 08:45 EST — [Immix Biopharma to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference) — Source: Immix Biopharma
- 2026-03-30 08:45 EST — [Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsed-refractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones) — Source: Immix Biopharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)